January 2026 FDA New Drug Approvals Zycubo (copper histidinate) Some approvals mark progress. Others redefine what hope looks like. In January 2026, the U.S. FDA approved Zycubo (copper histidinate injection formerly The FDA just changed the game for peptides. April 2026 The FDA is reviewing Category 2 peptides for potential removal from restricted status. Full approval for some peptides may be The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what Peptide Research Overview Mechanisms, Applications & Insights